PL BioScience has advanced an oral BPC-157 formulation (designated PL-10) to Phase II clinical trials for inflammatory bowel disease representing the most clinically advanced human development of oral BPC-157 to date.3 Human peer-reviewed results from these trials are pending, but the preclinical rationale is strong
K., Hocquard, A., Avila, G., Pagana, A., Chen, A., & John, T
At this time, GLP-1s are not RA med ications and should not replace standard rheumatology treatment
This was predominantly driven by the continuing roll-out of Novo Nordisks semaglutide and Lillys tirzepatide, and off-label use of their respective T2D-indicated brands
Family owned since 1968
Clin Pediatr 2011